Elizabeth Yeu Lin - 16 Jun 2023 Form 4 Insider Report for Tarsus Pharmaceuticals, Inc. (TARS)

Role
Director
Signature
/s/ Jeffrey Farrow, Attorney-in-Fact
Issuer symbol
TARS
Transactions as of
16 Jun 2023
Net transactions value
$0
Form type
4
Filing time
21 Jun 2023, 18:14:50 UTC
Previous filing
16 Jun 2023
Next filing
26 Jun 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TARS Common Stock Options Exercise +2,000 2,000 16 Jun 2023 Direct F1
holding TARS Common Stock 12,040 16 Jun 2023 By 401(k) Plan
holding TARS Common Stock 6,360 16 Jun 2023 By Spouse's Roth IRA

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TARS Restricted Stock Units Options Exercise $0 -2,000 -100% $0.000000* 0 16 Jun 2023 Common Stock 2,000 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock.
F2 Each RSU represents a contingent right to receive one share of the Company's common stock.
F3 RSUs granted on June 16, 2022, in connection with the Reporting Person's service as a non-employee director as of the Company's 2022 annual meeting of stockholders. The RSUs vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.

Remarks:

Exhibit 24 - Power of Attorney